Tuesday, Schering-Plough Corp., (SGP), a health care company, announced that corifollitropin alfa, its experimental, sustained follicle stimulant, or SFS, met its primary endpoints in the Phase III ENGAGE trial, which compared corifollitropin alfa 150 mcg to 200 IU follitropin beta.
Corifollitropin alfa is being developed as a potential treatment in Controlled Ovarian Stimulation for the development of multiple follicles and pregnancy in women participating in an Assisted Reproductive Technology program.
The primary endpoint in the trial was ongoing pregnancy rate assessed at 10 weeks or more after embryo transfer. The number of oocytes retrieved was the co-primary endpoint.
The company said the ongoing pregnancy rate obtained in the corifollitropin alfa treatment arm was 38.9% per started cycle, similar to that achieved in patients receiving follitropin beta.
The number of oocytes retrieved was within the limits of clinical equivalence, and the estimated difference of +1.2 was in favor of the corifollitropin alfa 150 mcg treatment arm, the company noted.
Schering-Plough stated that the incidence of ovarian hyperstimulation syndrome was similar between groups, 7.0% in the corifollitropin alfa group and 6.3% in the follitropin beta group.
Schering-Plough is currently trading at $20.56, up $0.62 or 3.11%.
For comments and feedback: editorial@rttnews.com